Abstract: OBJECTIVE To investigate the effect of tiotropium bromide inhalation powder (Spiriva) in treating bronchiectasis. To observe the influence of tiotropium bromide on inspiratory capacity(IC) and forced expiratory volume(FVC) in patients with brochiectasis and to investigate the value of IC, FVC in evaluating therapeutic effect of brochodilators. METHODS Thirty bronchiectasis patients were randomly divided into 2 groups: control group(n=14) and observation group(n=16), each group received conventional therapy. Besides of this, patients in treatment group were treated with tiotropium bromide 18 μg QD inhalation, the course of treatment was 6 months. Before treatment, general condition, the clinical symptoms, pulmonary function of two groups were evaluated. After treatment, pulmonary function, IC, FVC, FEV₁%pred, FEV₁/FVC, clinical symptom score, curative effect evaluation, the times of acute exacerbation, differences in adverse reaction were compared between two groups. RESULTS Pulmonary function, IC, FVC, FEV₁%pred were increased in both groups after treatment, there was significant difference(P<0.05), clinical symptom score was significantly higher than before treatment, the number of acute attack was significantly lower than that before treatment (P<0.05). The clinical symptom score, acute exacerbation frequency and pulmonary function of IC, FVC in treatment group were improved than the control group, there were significant differences between the two groups(P<0.05). No obvious adverse reactions were observed in two groups. CONCLUSION The combined use of tiotropium bromide in treatment of bronchiectasis can improve the pulmonary ventilation function of patients, relieve symptoms including cough, expectoration, shortness of breath, wheezing, and reduce the frequency of acute attack. Tiotropium bromide can increase IC, FVC of bronchiectasis patients. IC and FVC can assess the efficacy of bronchodilators as reliability index. They are more sensitive than FEV₁∕FVC, FEV1%pred.